|
|
Postoperative radiotherapy and chemotherapy in the
management of oligodendroglioma: single institutional review of 88 patients
Ozyigit
G, Onal
C, Gurkaynak
M, Soylemezoglu
F, Zorlu
F
Department of Radiation Oncology, Faculty of Medicine, Hacettepe University,
06100 Ankara, Turkey. gozyigit @hacettepe.edu.tr
We retrospectively evaluate the prognostic factors affecting the local
control, survival and the potential role of chemotherapy in the management
of patients with oligodendroglioma.
The medical records of 88 patients
treated by postoperative external beam radiotherapy +/- chemotherapy at our
institution between December 1993 and December 2002 were analyzed.
Nine
patients (10%) were treated with an accelerated fractionation scheme, while
79 patients were treated with conventional doses.
The median RT dose was
54.8 +/- 2.58 Gy for low-grade tumors, and 58.7 +/- 2.46 Gy for high-grade
tumors.
PCV chemotherapy regimen was given to 18 patients; temozolamide was
administered in three patients.
Chemotherapy was not given concomitantly in
any patients.
The median follow-up was 56 months (range 7-134 months).
The
5-year overall and progression-free survival rates for entire group were 86%
and 79%, respectively.
Patients with epilepsy at presentation had better
5-year overall survival (93% vs. 74%, P=0.04).
High grade tumors had
significantly lower overall survival rate.
Age, presence of motor deficit at
diagnosis and histological grade were found have a significant impact on
progression-free survival.
The 5-year overall and progression free survival
rates of patients with high-grade tumors were 69%, 51% and 74%, 68% for
chemotherapy and no-chemotherapy group, respectively (P=0.9 for OS, P=0.3
for PFS).
In multivariate analysis no significant factor affecting the
overall survival and progression-free survival was found.
Chemotherapy given
after postoperative radiotherapy in patients with oligodendroglioma did not
improve survival in this retrospective study.
|
